213 related articles for article (PubMed ID: 26096345)
1. Historical review on thymosin α1 in oncology: preclinical and clinical experiences.
Garaci E; Pica F; Matteucci C; Gaziano R; D'Agostini C; Miele MT; Camerini R; Palamara AT; Favalli C; Mastino A; Serafino A; Sinibaldi Vallebona P
Expert Opin Biol Ther; 2015; 15 Suppl 1():S31-9. PubMed ID: 26096345
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
3. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
Danielli R; Fonsatti E; Calabrò L; Di Giacomo AM; Maio M
Ann N Y Acad Sci; 2012 Oct; 1270():8-12. PubMed ID: 23050811
[TBL] [Abstract][Full Text] [Related]
4. Immunopharmacology of thymosin alpha1 and cytokine synergy.
Naylor PH; Quadrini K; Garaci E; Rasi G; Hadden JW
Ann N Y Acad Sci; 2007 Sep; 1112():235-44. PubMed ID: 17567942
[TBL] [Abstract][Full Text] [Related]
5. Thymosin alpha1. SciClone Pharmaceuticals.
Billich A
Curr Opin Investig Drugs; 2002 May; 3(5):698-707. PubMed ID: 12090542
[TBL] [Abstract][Full Text] [Related]
6. Thymosin alpha 1: from bench to bedside.
Garaci E; Favalli C; Pica F; Sinibaldi Vallebona P; Palamara AT; Matteucci C; Pierimarchi P; Serafino A; Mastino A; Bistoni F; Romani L; Rasi G
Ann N Y Acad Sci; 2007 Sep; 1112():225-34. PubMed ID: 17600290
[TBL] [Abstract][Full Text] [Related]
7. Effect of a C-end rule modification on antitumor activity of thymosin α1.
Wang F; Xu C; Peng R; Li B; Shen X; Zheng H; Lao X
Biochimie; 2018 Nov; 154():99-106. PubMed ID: 30096371
[TBL] [Abstract][Full Text] [Related]
8. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
9. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Liu F; Wang HM; Wang T; Zhang YM; Zhu X
BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
[TBL] [Abstract][Full Text] [Related]
11. Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1.
Yuan C; Zheng Y; Zhang B; Shao L; Liu Y; Tian T; Gu X; Li X; Fan K
Biochem Biophys Res Commun; 2015 Aug; 464(1):249-55. PubMed ID: 26111447
[TBL] [Abstract][Full Text] [Related]
12. Historical review of thymosin α 1 in infectious diseases.
Camerini R; Garaci E
Expert Opin Biol Ther; 2015; 15 Suppl 1():S117-27. PubMed ID: 26098768
[TBL] [Abstract][Full Text] [Related]
13. A Reappraisal of Thymosin Alpha1 in Cancer Therapy.
Costantini C; Bellet MM; Pariano M; Renga G; Stincardini C; Goldstein AL; Garaci E; Romani L
Front Oncol; 2019; 9():873. PubMed ID: 31555601
[TBL] [Abstract][Full Text] [Related]
14. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Mao L
Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach.
Naylor PH; Mutchnick MG
J Viral Hepat; 2018 Jan; 25(1):4-9. PubMed ID: 29052304
[TBL] [Abstract][Full Text] [Related]
16. Thymosin α1 and cancer: action on immune effector and tumor target cells.
Garaci E; Pica F; Serafino A; Balestrieri E; Matteucci C; Moroni G; Sorrentino R; Zonfrillo M; Pierimarchi P; Sinibaldi-Vallebona P
Ann N Y Acad Sci; 2012 Oct; 1269():26-33. PubMed ID: 23045967
[TBL] [Abstract][Full Text] [Related]
17. Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines.
Fan YZ; Chang H; Yu Y; Liu J; Wang R
Peptides; 2006 Sep; 27(9):2165-73. PubMed ID: 16644063
[TBL] [Abstract][Full Text] [Related]
18. Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.
Moody TW
Ann N Y Acad Sci; 2007 Sep; 1112():297-304. PubMed ID: 17567944
[TBL] [Abstract][Full Text] [Related]
19. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
